← Leaderboards
Brian J. McCarthy
Sloan-Kettering Inst Can Research
$846,430
Attributed
$1,692,859
Total exposure
1
Grants
0
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $576K · FY2018–20$1M$750K$500K$250K$0
'18
'19
'20
Funding mix
By agency
NIH$1,692,859 · 1
By mechanism
R01$1,692,859 · 1
Top collaborators
- Kenneth H. Yu3 shared
Most similar at Sloan-Kettering Inst Can Research
Same institution · by research overlap
- Jason S Lewis$26,024,327
- Charles L Sawyers$34,701,646
- Richard N Kolesnick$17,601,323
- David B. Solit$21,393,031
- Samuel Singer$8,089,401
Others in their field
Other Emerging Leaders on “Base”
- Sonia M Thomas · Research Triangle Institute$700,865,642
- Leonard Freedman · Leidos Biomedical Research, Inc.$515,995,429
- Tracy L Nolen · Research Triangle Institute$474,487,152
- Chanza Baytop · Westat, Inc.$271,217,917
- Valerie Koch · University Corporation For Atmospheric Res$247,762,266
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$211,662,224
Research focus
BaseBiobankBiological Response Modifier TherapyBiologyBiopsyBloodBlood TestsCancer EtiologyCellsCessation Of LifeChemotherapyChemotherapy-Oncologic ProcedureClinical TrialsCollaborationsColorectal CancerDeath RateDisease ProgressionEarly DiagnosisEffective TherapyFutureGemcitabineGenesGeneticAdvanced Pancreatic Cancer
Grant awards (3)
Pharmacogenomic and circulating tumor cell approach to individualized treatment of pancreatic cancer$575,997
R01 · FY2020 · CA
Pharmacogenomic and circulating tumor cell approach to individualized treatment of pancreatic cancer$558,719
R01 · FY2019 · CA
Pharmacogenomic and circulating tumor cell approach to individualized treatment of pancreatic cancer$558,143
R01 · FY2018 · CA